Burkholderia cepacia Complex Catheter-Related Bloodstream Infection: Duration of Therapy
For uncomplicated Burkholderia cepacia complex catheter-related bloodstream infection with catheter removal, treat for 7–14 days after the first negative blood culture, counting day 1 as the first day blood cultures are negative.
Treatment Duration Algorithm
Uncomplicated CRBSI (7–14 days)
Remove the catheter immediately and treat for 7–14 days after the first negative blood culture if all of the following criteria are met: 1, 2
- Blood cultures clear within 72 hours of catheter removal and appropriate antibiotics
- Fever resolves within 72 hours
- No evidence of endocarditis (by echocardiography if indicated)
- No suppurative thrombophlebitis
- No metastatic infection (vertebral osteomyelitis, septic arthritis, visceral abscesses)
- No intravascular hardware or prosthetic devices
Early catheter removal (within 3 days) is crucial for B. cepacia complex CRBSI, as delayed removal results in higher rates of persistent bacteremia (54.5% vs 26.1%) and lower clinical response rates (49.0% vs 71.9%). 2
Complicated CRBSI (4–6 weeks)
Extend therapy to 4–6 weeks if any of the following are present: 1
- Persistent bacteremia or fungemia >72 hours despite appropriate therapy and catheter removal
- Endocarditis
- Suppurative thrombophlebitis
- Metastatic infection
- Inability to remove the catheter
For osteomyelitis, treat for 6–8 weeks. 1
Antibiotic Selection
Empirical Therapy
- Initiate empirical broad-spectrum coverage with an anti-pseudomonal β-lactam (ceftazidime, meropenem, or piperacillin-tazobactam) plus an aminoglycoside for critically ill patients, those with sepsis, or suspected multidrug-resistant organisms. 1, 3
Definitive Therapy Based on Susceptibility
Trimethoprim-sulfamethoxazole is the preferred agent when susceptible (92.8% susceptibility rate), followed by piperacillin-tazobactam (90.3% susceptibility). 2, 4
Ceftazidime (75.5% susceptibility) or meropenem (72.3% susceptibility) are alternative options based on susceptibility testing. 2, 4
Minocycline shows excellent activity (100% susceptibility in some series) and can be considered for resistant isolates. 5
De-escalate from combination therapy to monotherapy within 24–72 hours once susceptibility results are available and clinical improvement is evident. 3, 6
Critical Management Principles
Catheter Management
Catheter removal is mandatory for B. cepacia complex CRBSI—this is a gram-negative bacillus that behaves similarly to Pseudomonas aeruginosa and requires immediate catheter removal. 1, 2
Do not attempt catheter salvage with antibiotic lock therapy for B. cepacia complex, as this organism requires catheter removal for optimal outcomes. 2
Monitoring Requirements
Obtain follow-up blood cultures at 48–72 hours to document clearance of bacteremia. 1, 6
Day 1 of therapy duration is counted from the first negative blood culture, not from the initiation of antibiotics. 1
Repeat blood cultures 1 week after completing antibiotics if there is concern for relapse or if the catheter was retained (though retention is not recommended for B. cepacia). 1
Common Pitfalls to Avoid
Do not delay catheter removal beyond 3 days, as this significantly worsens outcomes in B. cepacia complex CRBSI. 2
Do not automatically extend therapy to 4–6 weeks if blood cultures clear within 72 hours and all uncomplicated criteria are met—this increases risk of adverse events without benefit. 1, 6
Do not use fluoroquinolones empirically due to resistance rates of 36% in B. cepacia complex. 2, 4
Do not underestimate the severity of B. cepacia complex BSI—mortality rates are 16% at 14 days, 25% at 30 days, and 36% at 90 days, even with appropriate therapy. 4